Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet transfusion therapy.

S J Slichter1

  • 1Division of Hematology, University of Washington School of Medicine, Seattle.

Hematology/Oncology Clinics of North America
|February 1, 1990
PubMed
Summary
This summary is machine-generated.

This review covers platelet transfusions for patients with chronic low platelet counts due to decreased production, such as those undergoing chemotherapy or bone marrow transplants. It details transfusion products, indications, expected responses, and managing refractoriness.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial.

Vox sanguinis·2016
Same author

Further studies to evaluate methods of leucoreduction to prevent alloimmune platelet refractoriness and induce tolerance in a dog platelet transfusion model.

Vox sanguinis·2016
Same author

Extended storage of autologous apheresis platelets in plasma.

Vox sanguinis·2013
Same author

Platelet transfusion: future directions.

Vox sanguinis·2004
Same author

Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin.

Blood·2001
Same author

Universal WBC reduction.

Transfusion·2000
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Transfusion Medicine

Background:

  • Patients undergoing chemotherapy, radiation, or bone marrow transplants often experience chronic thrombocytopenia due to decreased platelet production.
  • Effective platelet support is crucial for managing bleeding risks in these vulnerable patient populations.

Purpose of the Study:

  • To review appropriate platelet support strategies for chronically thrombocytopenic patients.
  • To discuss available platelet transfusion products and their indications.
  • To cover expected transfusion responses, alloimmunization prevention, and management of platelet refractoriness.

Main Methods:

  • Literature review of current practices and evidence regarding platelet support.
  • Discussion of clinical guidelines and expert consensus on transfusion indications.

Related Experiment Videos

  • Analysis of mechanisms and management strategies for platelet refractoriness.

    • Main Results:

    • Comprehensive overview of platelet transfusion products and their appropriate use.
    • Guidelines for initiating platelet transfusions based on clinical context and platelet counts.
    • Strategies for preventing and managing platelet alloimmunization and refractoriness.

    Conclusions:

    • Optimizing platelet support is essential for patients with decreased platelet production, particularly those in active cancer treatment or post-transplant.
    • Understanding transfusion products, indications, and potential complications like refractoriness improves patient outcomes.
    • Proactive management of alloimmunization and refractoriness is key to sustained therapeutic efficacy.